Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[UGT1A1 Genotyping for Proper Use of Irinotecan].

Rinsho byori. The Japanese journal of clinical pathology - 1 Jul 2015

Matsuoka Ayumu, Ando Yuichi

Abstract excerpt

Irinotecan is a camptothecin analog used worldwide for a broad range of solid tumors, including colorectal and lung cancers. It can cause severe adverse drug reactions, such as neutropenia or diarrhea. Irinotecan is metabolized to form active SN-38, which is further conjugated and detoxified by the UDP-glucuronosyltransferase (UGT) 1A1 enzyme. Recent pharmacogenetic studies on irinotecan have revealed the impact...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Genotype
Share to Glucuronosyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Irinotecan

Share to Neutropenia

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 26591441

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[UGT1A1 Genotyping for Proper Use of Irinotecan].PMID 26591441Read ↗

[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Clinical Pharmacogenetics of Irinotecan (CPT-11)Semantic proximity Read ↗

Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.Semantic proximity Read ↗

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Semantic proximity Read ↗

Pharmacogenetic approach for cancer treatment-tailored medicine in practice.Semantic proximity Read ↗

Insights, challenges, and future directions in irinogenetics.Semantic proximity Read ↗

[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.